Back to PRICE T ROWE ASSOCIATES INC /MD/ PRICE T ROWE ASSOCIATES INC /MD/

PTGXPTGX
26 quarters

Position history for PRICE T ROWE ASSOCIATES INC /MD/PRICE T ROWE ASSOCIATES INC /MD/'s holdings in PROTAGONIST THERAPEUTICS INC

Yes. Price T Rowe Associates holds 2,149,662 shares of PTGX (Protagonist Therapeutics), worth $263.5M, as of its Q2 2026 13F filing. It increased the position by 484,165 shares (+29.1%) from Q1 2026. Price T Rowe Associates has held PTGX since Q1 2023, across 14 quarterly 13F filings.

Current Value

$263.5M

Current Shares

2.1M

Total Value Change

+$263.2M

Total Shares Change

+2.1M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
2.1M
+29.1%
$263.5M0.0%$122.58
39
2026-Q1
Increased
1.7M
+18.9%
$175.5M0.0%$105.40
36
2025-Q4
Increased
1.4M
+14.8%
$122.3M0.0%$87.34
34
2025-Q3
Increased
1.2M
+30.3%
$81.1M0.0%$66.43
38
2025-Q2
Decreased
936,703
-29.1%
$51.8M0.0%$55.27
0
2025-Q1
Decreased
1.3M
-5.1%
$63.9M0.0%$48.36
0
2024-Q4
Increased
1.4M
+6.3%
$53.8M0.0%$38.60
31
2024-Q3
Increased
1.3M
+8.3%
$58.9M0.0%$45.00
32
2024-Q2
Increased
1.2M
+47.6%
$41.9M0.0%$34.65
40
2024-Q1
Decreased
819,296
-0.5%
$23.7M0.0%$28.93
0
2023-Q4
Decreased
823,740
-1.0%
$18.9M0.0%$22.93
0
2023-Q3
Increased
831,993
+0.0%
$13.9M0.0%$16.68
28
2023-Q2
Increased
831,693
+100.3%
$23M0.0%$27.62
46
2023-Q1
New
415,274
-
$9.6M0.0%$23.00
38
2022-Q2
Exited
0
-100.0%
$00.0%$7.91
0
2022-Q1
Decreased
300,468
-20.3%
$7.1M0.0%$23.68
0
2021-Q4
Decreased
377,132
-23.3%
$12.9M0.0%$34.20
0
2021-Q3
Decreased
491,641
-50.1%
$8.7M0.0%$17.72
0
2021-Q2
Increased
986,254
+8.0%
$44.3M0.0%$44.88
32
2021-Q1
Increased
913,590
+8.1%
$23.7M0.0%$25.90
31
2020-Q4
Increased
845,395
+44.3%
$17M0.0%$20.16
38
2020-Q3
Decreased
585,859
-21.6%
$11.5M0.0%$19.55
0
2020-Q2
Increased
747,634
+1654.3%
$13.2M0.0%$17.66
45
2020-Q1
Increased
42,616
+0.2%
$301,0000.0%$7.06
16
2019-Q4
Increased
42,516
+55.4%
$300,0000.0%$7.05
23
2019-Q3
First report
27,365
-
$329,0000.0%$12.01
0

Other major holders of PTGX: BlackRock, Inc., FARALLON CAPITAL MANAGEMENT, L.L.C.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used